Activity of bromodomain protein inhibitors/binders against asexual-stage Plasmodium falciparum parasites. Issue 2 (August 2018)

• Record Type: Journal Article
• Authors: Chua, Ming Jang; Robaa, Dina; Skinner-Adams, Tina S.; Sippl, Wolfgang; Andrews, Katherine T.
• Is Part Of: International journal for parasitology. Volume 8:Issue 2(2018)
• Page Start: 189
• Page End: 193
• Publication Date: 2018-08
• Subjects: Plasmodium falciparum -- Anti-plasmodial activity -- Bromodomain protein inhibitor; Parasitic diseases -- Chemotherapy -- Periodicals; Drug resistance -- Periodicals; 616.96061
• DOI: 10.1016/j.ijpddr.2018.03.001
• Languages: English
• ISSNs: 2211-3207

Abstract

Abstract: Bromodomain-containing proteins (BDPs) are involved in the regulation of eukaryotic gene expression. Compounds that bind and/or inhibit BDPs are of interest as tools to better understand epigenetic regulation, and as possible drug leads for different diseases, including malaria. In this study, we assessed the activity of 42 compounds demonstrated or predicted (using virtual screening of a pharmacophore model) to bind/inhibit eukaryotic BDPs for activity against Plasmodium falciparum malaria parasites. In silico docking studies indicated that all compounds are predicted to participate in a typical hydrogen bond interaction with the conserved asparagine (Asn1436) of the P. falciparum histone acetyltransferase ( Pf GCN5) bromodomain and a conserved water molecule. Only one compound (the dimethylisoxazole SGC-CBP30; a selective inhibitor of CREBBP (CBP) and EP300 bromodomains) is also predicted to have a salt-bridge between the morpholine nitrogen and Glu1389. When tested for in vitro activity against asynchronous asexual stage P. falciparum Dd2 parasites, all compounds displayed 50% growth inhibitory concentrations (IC50 ) >10 μM. Further testing of the three most potent compounds using synchronous parasites for 72 h showed that SGC-CBP30 was the most active (IC50 3.2 μM). In vitro cytotoxicity assays showed that SGC-CBP30 has ∼7-fold better selectivity for the parasites versus a human cell line (HEK 293). Together these data provide a possible starting point for future investigation of these, or related compounds, as tools to understand epigenetic regulation or as potential new drug leads. Graphical abstract: Image 1 Highlights: 42 demonstrated or predicted BDP binders/inhibitors investigated. In silico docking predicts all have hydrogen bond interaction with conserved Asn1436 of PfGCN5 bromodomain. Pan-bromodomain inhibitor SGC-CBP30 also has predicted salt-bridge between morpholine nitrogen and Glu1389. SGC-CBP30 has most potent in vitro activity against asexual-stage P. falciparum (IC50 3.2 μM). SGC-CBP30 has ∼7-fold better selectivity for P. falciparum versus HEK 293 cell.